AAAAI News: Early Skin Microbiome and Metabolome Signatures May Predict AD in Infants
Early skin microbiome and metabolome signatures can predict atopic dermatitis in infants aged 6 to 18 months old, according to new research being presented at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting. The Singapore Preconception Study of Long-Term Maternal and Child Outcomes (S-PRESTO) mother-offspring cohort profiled bacterial metagenomics, antimicrobial peptides (AMPs) […]
Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD
Contrary to concerns regarding malignancy, venous thromboembolism, and major adverse cardiac events, the use of Janus kinase (JAK) inhibitors is not associated with a significant increase in the overall risk for these conditions in patients with atopic dermatitis (AD), according to a systematic review and meta-analysis, published in the Journal of the European Academy of Dermatology & Venereology. Recently, […]
Research Seeks to Understand How Climate Change Affects AD, Other Allergic Conditions
Global warming and other environmental changes may be contributing to rising rates of epithelial barrier dysfunction and atopic dermatitis (AD). This is among the main messages from research published in a themed issue of Annals of Allergy, Asthma & Immunology. When the epithelial barrier is disrupted, it facilitates the entry of the external exposome into and […]
FDA Green Lights Leo’s Adbry for Kids With AD
The U.S. Food and Drug Administration (FDA) has expanded the approval of tralokinumab-ldrm (Adbry, LEO Pharma Inc) to include kids aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry is the first and only FDA-approved biologic that specifically […]
Almirall, Etherna Partner to Develop mRNA-based Therapies in Medical Dermatology
Almirall, S.A. (ALM) and etherna are teaming up to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The alliance combines and leverages etherna’s proprietary mRNA capabilities and lipid nanoparticle (LNP) formulations with Almirall’s medical dermatology expertise to accelerate discovery of novel treatment options. Etherna and Almirall will work collaboratively on the research […]